Sign in
Not yet recruitingPhase 1

A study to assess the safety of ARGX-118 in healthy adults and adults with Allergic Bronchopulmonary Aspergillosis (ABPA)

Key facts

Who runs it
Argenx
Where
Belgium2 sites in 1 countryChoose a country to see its sites
Status
Not yet recruiting
Phase
Phase 1
People taking part
112 people, planned
Started
17 Nov 2026
Expected to end
15 May 2029
Type of study
Interventional
Record updated
18 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Allergic bronchopulmonary aspergillosis

Where is this trial?

It has sites in one country. Choose a country to see its sites.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Criteria questions
Built from 2026-525870-20-00, who can take part
Record updated
18 November 2026